Board of Directors
Client Team Lead: Zach Charles
Client: CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has appointed Bettina M. Cockroft, M.D., M.B.A., to its Board of Directors as an independent director.
Dr. Cockroft is a well-established industry executive with over 30 years of experience in the biopharmaceutical industry with clinical development expertise across multiple therapeutic areas. Over the course of her notable career, she has successfully led multiple clinical development programs and has a proven track record executing programs through drug development, commercial launch and beyond, having played a key role in the approval of several drugs for neurological, cardiovascular and infectious diseases.
“On behalf of the CNS Pharmaceuticals Board and management, we are thrilled to welcome Dr. Cockroft to the Board. Her appointment adds deep scientific, clinical and operational expertise, and we believe that she will provide an integral viewpoint and invaluable guidance,” commented Faith L. Charles, Chair of the CNS Pharmaceuticals Board of Directors. “Dr. Cockroft’s addition to our team is another representation of our commitment to advancing Berubicin and the Company’s planning for success in order to serve patients in desperate need of a treatment, as well as building value for shareholders in the near and long term. Additionally, her European training provides an important perspective on our expanding clinical operations in that important region. We look forward to leveraging her proven leadership and extensive expertise moving forward.”
Dr. Cockroft has served as the Senior Vice President and Chief Medical Officer of Sangamo Therapeutics, Inc. since 2019, overseeing all clinical development activities, clinical operations and drug safety. Prior to joining Sangamo, Dr. Cockroft served on the senior leadership team as Vice President, Clinical Research, Neurology at Cytokinetics, Inc., where she was responsible for clinical development of fast skeletal muscle troponin activators in diseases such as Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy. Before that, Dr. Cockroft served as Chief Medical Officer of Auris Medical AG, where she led and grew the clinical development team responsible for two Phase 3 programs. Dr. Cockroft also held roles of increasing responsibility at Merck Serono S.A., Novartis Consumer Health and Menarini Ricerche earlier in her career. Additionally, she has authored or co-authored over 20 publications and currently serves as a member of the Board of Directors for Annexon Biosciences.
“Joining the Board at CNS Pharmaceuticals at this time represents an exciting opportunity for me. The team’s continued commitment to the GBM community and the advancement of the development of Berubicin as a potential much-needed treatment solution is nothing short of inspiring and I look forward to working closely with the team to play a role in continuing its momentum forward and driving Berubicin towards approval,” added Dr. Cockroft.
Dr. Cockroft received her M.B.A. from the MIT Sloan School of Management and her M.D. from the University of Genova.
Ready to realize your future?